A Phase I study of AZD1480 in Patients with Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the escalation phase,Non-Small Cell Lung Cancer(NSCLC) and non-smokers with lung metastasis and gastric cancer and solid tumour in the expansion phase.

Inclusion Criteria

• - Male or female aged 18 years or older
• - For Part A and C: Histological or cytological confirmation of a solid malignant tumour refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
• - For Expansion : Histological or cytological confirmation of
• - Expansion 1: EGFR and/or ROS mutant NSCLC or Non-smokers with lung metastasis
• - Expansion 2: Gastric cancer or solid tumour with biopsy available (consenting paired biopsies)refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
• - For Part B : Advanced or metastatic HCC, unresectable and incurable with ablative therapy or TACE, with no standard therapy available.
• - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks
• - For Part B : Child-Pugh liver function status classified as A to B7